These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 3138431)
61. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Kalifa C; Hartmann O; Demeocq F; Vassal G; Couanet D; Terrier-Lacombe MJ; Valteau D; Brugieres L; Lemerle J Bone Marrow Transplant; 1992 Apr; 9(4):227-33. PubMed ID: 1534708 [TBL] [Abstract][Full Text] [Related]
62. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169 [TBL] [Abstract][Full Text] [Related]
63. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study. Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282 [TBL] [Abstract][Full Text] [Related]
64. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656 [TBL] [Abstract][Full Text] [Related]
65. A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Ellis ED; Williams SF; Moormeier JA; Kaminer LS; Bitran JD Bone Marrow Transplant; 1990 Dec; 6(6):439-42. PubMed ID: 1982927 [TBL] [Abstract][Full Text] [Related]
66. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. Moormeier JA; Williams SF; Kaminer LS; Garner M; Bitran JD J Natl Cancer Inst; 1990 Jan; 82(1):29-34. PubMed ID: 1967148 [TBL] [Abstract][Full Text] [Related]
67. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839 [TBL] [Abstract][Full Text] [Related]
68. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Stiff PJ; Bayer R; Tan S; Camarda M; Sosman J; Peace D; Kinch L; Rad N; Loutfi S Clin Cancer Res; 1995 Dec; 1(12):1495-502. PubMed ID: 9815949 [TBL] [Abstract][Full Text] [Related]
69. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study. Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165 [No Abstract] [Full Text] [Related]
70. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen. Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964 [TBL] [Abstract][Full Text] [Related]
71. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935 [TBL] [Abstract][Full Text] [Related]
72. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study]. Shi Y; Pan F; Han X Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500 [TBL] [Abstract][Full Text] [Related]
73. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Papadakis V; Dunkel IJ; Cramer LD; Kramer E; Papadopoulos E; Goldman S; Packer RJ; Willoughby M; Baker D; Garvin J; Strandjord S; Coccia P; Kaplan AM; Klemperer M; Finlay JL Bone Marrow Transplant; 2000 Jul; 26(2):153-60. PubMed ID: 10918425 [TBL] [Abstract][Full Text] [Related]
74. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. van der Wall E; Horn T; Bright E; Passos-Coehlo JL; Bond S; Clarke B; Altomonte V; McIntyre K; Vogelsang G; Noga SJ; Davis JM; Thomassen J; Ohly KV; Lee SM; Fetting J; Armstrong DK; Davidson NE; Hess AD; Kennedy MJ Br J Cancer; 2000 Dec; 83(11):1405-11. PubMed ID: 11076645 [TBL] [Abstract][Full Text] [Related]
75. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869 [TBL] [Abstract][Full Text] [Related]
76. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439 [TBL] [Abstract][Full Text] [Related]
77. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. Heideman RL; Douglass EC; Krance RA; Fontanesi J; Langston JA; Sanford RA; Kovnar EH; Ochs J; Kuttesch J; Jenkins JJ J Clin Oncol; 1993 Aug; 11(8):1458-65. PubMed ID: 8336185 [TBL] [Abstract][Full Text] [Related]
78. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217 [TBL] [Abstract][Full Text] [Related]
79. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. Wilson WH; Jain V; Bryant G; Cowan KH; Carter C; Cottler-Fox M; Goldspiel B; Steinberg SM; Longo DL; Wittes RE J Clin Oncol; 1992 Nov; 10(11):1712-22. PubMed ID: 1403054 [TBL] [Abstract][Full Text] [Related]
80. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Przepiorka D; Dimopoulos M; Smith T; Ippoliti C; Diener K; Luna M; Champlin RE Ann Hematol; 1994 Apr; 68(4):183-8. PubMed ID: 8003559 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]